
## Drugs used in Congestive Heart Failure




By Mangesh A. Mapari

## Congestive Heart Failure (CHF)

- When a heart fails to pump blood in a quantity sufficient to fulfil the body requirements, a condition of Congestive Heart Failure (CHF) occurs, which is also known as a Heart Failure (HF).
- Change in electrophysiology of heart.
- ✓ Narrowing of the arteries, supplying blood to the heart muscles,
- ✓ The patient suffered in the past with myocardial infarction or heart attack with the injured tissue that obstructs the normal functioning of heart,
- ✓ Any congenital heart defects,
- ✓ Endocarditis (infection in heart valve) or myocarditis (infection of heart muscles)

#### Classification




## Cardiac Glycosides

- Cardiac glycosides are derived from the foxglove plant (*Digitalis purpurea* ).
- William Withering described the therapeutic benefits of digitalis in 1785.
- Primarily, digitalis was used for treating dropsy, an old word for oedema. Further investigations established that digitalis was most helpful for oedema caused by weakened heart (i.e., heart failure).

### Structures of Cardiac Glycosides

- The sugar which is known as glycone and
- The nonsugar which consists of steroid and lactone ring known as aglycone moieties




### Cardiac glycosides are categorised into

Cardenolides and Bufadienolides

### Cardenolides

- A cardenolide is a type of steroid.
- Cardenolides (cardiac glycosides derived fr om plants) have a 5 membered α,β-unsaturated lactone ring. OR
- CG having the lactone 2-furanone is known as cardenolides.

### Bufadienolides




- Bufadienolides (cardiac glycosides derived from animals) have a 6 membered lactone ring with two conjugated double bonds (generally referred to as α-pyrone). OR
- Those having the lactone 2-pyrone are known as bufadienolides
- Bufadienolides are present in the secretions from the skin of toad species, thus, are referred to as toad poison.

## Digoxin

Digoxin is a purified **Cardinolide** cardiac glycoside, derived from the leaves of **digitalis** plant.

### Digoxin

#### Mechanism of Action



# Digoxin Mechanism of Action

- Digoxin inhibits the Na +-K+-ATPase membrane pump and increases the intracellular Na+ ions.
- The sodium calcium exchanger tries to extrude the Na+ ions and pumps in more Ca2+ ions, thereby increasing the intracellular concentrations of Ca2+ ions.


# Digoxin Mechanism of Action

- This promotes the activation of contractile proteins (e.g., actin and myosin).
- Digoxin also acts on the electrical activity of the heart, increases the slope of phase 4 depolarisation, shortens the action po tential duration, and decreases the maximal diastolic potential.

### Digoxin Uses

- It is used for treating and managing congestive cardiac insufficiency, heart failure, and arrhythmias.
- It is also used to treat a certain type of irregular heartbeat (chronic atrial fibrillation)






## Digitoxin

- Digitoxin is a cardiac glycoside which is occasionally used in place of digoxin.
- Its half -life is longer than digoxin, and toxic effects similar to digoxin lasts longer.

HOMM, 
$$CH_2$$
  $CH_2$   $C$ 

# **Digitoxin**Mechanism of Action




# **Digitoxin**Mechanism of Action

- Digitoxin inhibits the Na+-K+-ATPase membrane pump and increases the intracellular concentration of Na+ and Ca2+ ions.
- This increased intracellular concentration of Ca2+ ions activate the contractile proteins (e.g., actin and myosin).
- Digitoxin also acts on the electrical a ctivity of the heart, increases the slope of phase 4 depolarisation, shortens the action po tential duration, and decreases the maximal diastolic potential.

# Digitoxin Uses


• It is used for treating and managing congestive cardiac insufficiency, heart failure, and arrhythmias.






### Nesiritide

- Nesiritide is the recombinant form of **32** amino acid human B -type natriuretic peptide.
- It is obtained by ventricular myocardium.



# Nesiritide MOA




Smooth muscle cell relaxation

### Nesiritide Mechanism of Action

- Nesiritide is a Natriuretic Peptide (BNP) binds to the particulate guanylate cyclase receptor of vascular smooth muscles and endothelial cells.
- This increases the intracellular concentration of **guanosine 3'5' cyclic monophosphate** (cGMP)and smooth muscle cell relaxation.
- The cGMP serves as a second messenger to dilate veins and arteries. Nesiritide relax es isolated human arterial and venous tissue preparations pre -contracted with either endothelin -1 or phenylephrine (α-adrenergic agonist).

### Nesiritide Uses


• It is used for treating acute decompensated congestive heart failure in patients having with dyspnoea at rest or with minimum activity, such as talking, eating ,and bathing.




#### Bosentan

- Bosentan is a pyrimidines derivatives
- Bosentan is a endothelin receptor antagonist.
- It is essential ly used for treating Pulmonary Artery Hypertension (PAH).

### Bosentan MOA



### Bosentan MOA




### Bosentan MOA

- Endothelin-1 (ET -1) is a neurohormone. It produces its effects by binding to **ET<sub>A</sub> and ET<sub>B</sub>** receptors in the endothelium and vascular smooth muscles.
- The levels of ET-1 in plasma and lung tissue increase in patients having pulmonary arterial hypertension .
- Bosentan is a specific and competitive antagonist of endothelin ET<sub>A</sub> and ET <sub>B</sub> receptor, having a comparatively high affinity for ET<sub>A</sub> receptors.

### Bosentan Uses


• It is used for treating pulmonary arterial hypertension.



#### **Tezosentan**

- Tezosentan is an antagonist of endothelin  $\mathbf{ET_A}$  and  $\mathbf{ET_B}$  receptors.
- It acts as a vasodilator.
- It is designed to be used intravenously in patients with acute heart failure.

### Tezosentan MOA



Endothelin-1 (ET-1)

#### Tezosentan

#### Mechanism of Action

- Tezosentan relaxes the smooth muscle s in blood vessels, and dilates them.
- This dilation of arterial (resistance) vessels reduces systemic vascular resistance, and ultimately leads to fall in arterial blood pressure.
- Dilation of venous (capacitance) vessels decreases venous blood pressure.

### Tezosentan Uses

• It is designed to be used intravenously in patients with acute heart failure.